Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4336665 | 0.98 | CYP19A1 (0.46) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4185103 | 0.77 | SLC6A2 (0.35) | CYP19A1SLC6A2SLC6A4SLC6A3MAPT | |
| SCHEMBL544445 | 0.77 | TSHR (0.46) | SMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL9489967 | 0.77 | TSHR (0.46) | SMN1; SMN2ALDH1A1MAPK1KMT2A | |
| SCHEMBL140368 | 0.75 | CFTR (0.52) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7021489 | 0.75 | CYP19A1 (0.55) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6352964 | 0.72 | CYP19A1 (0.39) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9188938 | 0.72 | CCR1 (0.42) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2493545 | 0.72 | CFTR (0.58) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23539519 | 0.72 | CFTR (0.48) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107739375-B | Preparation and application of novel quinolizine pH fluorescent molecular probe | 四川大学 | 2020-09-22 | — | — | CN | disclosed |
| EP-1661897-B1 | PYRROLOPYRIMIDINONE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| CN-1871240-B | Pyrrolopyrimidine thion derivatives | TEIJIN PHARMA LTD | 2012-11-07 | — | — | CN | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7557113-B2 | Substituted pyrrolo[3,2-d]pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| CN-101394853-A | Use of pyrazolo [1, 5-a ] pyrimidin-7-ylamine derivatives in the treatment of neurological disorders | NOVARTIS AG (CH) | 2009-03-25 | — | — | CN | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| EP-1993552-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |
| CN-1909908-A | Pyrazolo [1, 5-a ] pyrimidin-7-yl-amine derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| CN-1871240-A | Pyrrolopyrimidine thion derivatives | TEIJIN PHARMA LTD (JP) | 2006-11-29 | — | — | CN | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1661897-A1 | PYRROLOPYRIMIDINONE DERIVATIVE | Teijin Pharma Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-1997049706-A1 | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF | NOVARTIS AG (CH) | 1997-12-31 | — | — | WO | disclosed |
| US-4228097-A | Method of preparing α-hydroxymethylene nitriles | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | CYP19A1 3274/4885CFTR 1757/4885SLC6A2 1099/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | CYP19A1 1345/4885CFTR 1450/4885SLC6A2 2991/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | CYP19A1 1345/4885CFTR 1450/4885SLC6A2 2991/4885 |
| US-20060160831-A1 | Pyrrolopyrimidinone derivatives | GSK3B, GSK3A, GSKIP | CYP19A1 810/4885CFTR 4778/4885SLC6A2 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.